An increase in CD8+ T cell miR-155 expression was also noted in tumor-bearing mice following bortezomib administration, although to a lesser degree by about 4.5-fold when compared with CD8+ T cells from tumor-bearing mice treated with saline (Figure 2B). Here, CD8A is linked to neoplasm.